Xanthomonas Maltophila

''Stenotrophomonas maltophilia'' is an aerobic, nonfermentative, Gram-negative bacterium. It is an uncommon bacterium and human infection is difficult to treat. Initially classified as ''Bacterium bookeri'', then renamed ''Pseudomonas maltophilia'', ''S. maltophilia'' was also grouped in the genus ''Xanthomonas'' before eventually becoming the type species of the genus ''Stenotrophomonas'' in 1993.

''S. maltophilia'' is slightly smaller (0.7–1.8 × 0.4–0.7 μm) than other members of the genus. They are motile due to polar flagella, and grow well on MacConkey agar producing pigmented colonies. ''S. maltophilia'' is catalase-positive, oxidase-negative (which distinguishes it from most other members of the genus) and has a positive reaction for extracellular DNase.

''S. maltophilia'' is ubiquitous in aqueous environments, soil, and plants; it has also been used in biotechnology applications. In immunocompromised patients, ''S. maltophilia'' can lead to nosocomial infections. It is also an emerging nosocomial pathogen associated with opportunistic infections in patients with cystic fibrosis, cancer, and HIV. Adherence of this organism to abiotic surfaces such as medical implants and catheters represents a major risk for hospitalized patients.

Pathogenesis

''S. maltophilia'' frequently colonizes humid surfaces such as the tubes used in mechanical ventilation and indwelling urinary catheters, as well as medical devices such as suction catheters and endoscopes. Infection is usually facilitated by the presence of prosthetic material (plastic or metal), and the most effective treatment is removal of the prosthetic material (usually a central venous catheter or similar device). ''S. maltophilia'' adheres strongly and forms biofilm on plastic surfaces although these abilities may vary greatly between strains. Hydrophobicity was correlated to successful adhesion and biofilm formation on polystyrene surfaces. ''S. maltophilia'' frequently co-occurs and forms multispecies biofilms with ''Pseudomonas aeruginosa''. ''S. maltophilia'' substantially influences the architecture of ''P. aeruginosa'' structures, causing development of extended filaments. These changes arise due to diffusible signalling factor encoded by ''S. maltophilia''.

The growth of ''S. maltophilia'' in microbiological cultures of respiratory or urinary specimens is difficult to interpret due to its low pathogenicity, and is not proof of infection. If, however, it is grown from sites which would be normally sterile (e.g., blood), then it usually represents true infection. ''S. maltophilia'' can be found in the flora of captive snakes.

In immunocompetent individuals, ''S. maltophilia'' is a relatively unusual cause of pneumonia, urinary tract infection, or bloodstream infection; in immunocompromised patients, however, ''S. maltophilia'' is a growing source of latent pulmonary infections. ''S. maltophilia'' colonization rates in individuals with cystic fibrosis have been increasing.

Deliberate induction of inflammatory responses is the main pathogenic mechanism of ''S. maltophilia'' infection. ''S. maltophilia'' secretes outer membrane vesicles (OMVs), that cause an inflammatory response. OMVs from ''S. maltophilia'' ATCC 13637 were found to be cytotoxic to human lung epithelial cells. These OMVs stimulate the expression of proinflammatory cytokine and chemokine genes, including interleukin (IL)-1''β'', IL-6, IL-8, tumor necrosis factor-''α'' and monocyte chemoattractant protein-1.

Treatment

''S. maltophilia'' is naturally resistant to many broad-spectrum antibiotics (including all carbapenems) due to the production of two inducible chromosomal metallo-β-lactamases (designated L1 and L2). This makes treatment of infected patients very difficult. ''S. maltophilia'' is ubiquitously present in the environment and impossible to eradicate, which makes prevention also extremely difficult.

Sensitivity testing requires nonstandard culture techniques (incubation at 30 °C). Testing at the wrong temperature results in isolates being incorrectly reported as being susceptible when they are, in fact, resistant. Disc diffusion methods should not be used, as they are unreliable, and agar dilution should be used instead.

''S. maltophilia'' is not a virulent organism and removal of the infected prosthesis is frequently sufficient to cure the infection; antibiotics are only required if the prosthesis cannot be removed. Many strains of ''S. maltophilia'' are sensitive to co-trimoxazole and ticarcillin, though resistance has been increasing. It is usually susceptible to piperacillin and ceftazidime. Tigecycline is also an effective drug. Polymyxin B may be effective treatment, at least ''in vitro'', though not without frequent adverse effects.

Epidemiology

''Stenotrophomonas'' infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals. Risk factors associated with ''Stenotrophomonas'' infection include HIV infection, malignancy, cystic fibrosis, neutropenia, mechanical ventilation, central venous catheters, recent surgery, trauma, prolonged hospitalization, intensive care unit admission and broad-spectrum antibiotic use.

History

''Stenotrophomonas maltophilia'' has had multiple different names in the past. It was first found in a pleural effusion in 1943 and given the name ''Bacterium bookeri''. It was then renamed to ''Pseudomonas maltophilia'' in 1961. It was moved to the genus ''Xanthomonas'' in 1983, and most recently to ''Stenotrophomonas'' in 1993.

References

External links

''Stenotrophomonas maltophilia'' article
at eMedicine.

The genus ''Stenotrophomonas''Stenotrophomonas Genome Projects
fro
Genomes OnLine DatabaseEffect of different antibiotics eg minocycline, Tigecycline
JAC 2002 correspondence
Type strain of ''Stenotrophomonas maltophilia'' at Bac''Dive'' - the Bacterial Diversity Metadatabase

{{DEFAULTSORT:Stenotrophomonas Maltophilia
Xanthomonadales
Bacteria described in 1993